Axis Bio recognises the importance of not only understanding the pharmacokinetic properties of your novel compounds but also the importance of target engagement in tumour-bearing animals. Together with our partners at XenoGesis, we can help you design PK-PD studies in a rational manner. By modelling single dose PK data, we can predict a dose and schedule that will give exposure above a target concentration identified from in vitro assays. We can help identify both the concentration and frequency of dosing required to ensure your compounds will have the best opportunity of succeeding in tumour growth delay studies.
Axis Bio’s flexible business models mean that in association with our preferred partners, we can perform full PK/PD studies consisting of plasma bioanalysis and tumour target engagement assessment, or we can simply carry out the in-life phase and return collected samples to our client for analysis.